论文部分内容阅读
用基因工程重组的人生长激素治疗垂体性侏儒症（GHD）13例6个月，所有患儿身高都有不同程度增加。平均共增高8．3±1．2cm，身高落后值（SDS）由治疗前的-5．51±0．94减少到治疗后的-4．20±0．96。在6个月的用药期，13例患儿身高增长速率明显增加，为16．6±2．4cm·y-1，与治疗前24±0.6cm·y-1相比增加非常明显（P＜0．001）。除少数患者用药初期与注射部位皮肤出现暂时性红斑外，未见其他不良反应。
13 cases of pituitary dwarfism (GHD) were treated with genetically engineered recombinant human growth hormone for 6 months. All children had increased body height to varying degrees. The average increase of 8.3 ± 1.2cm, height behind value (SDS) decreased from -5.51 ± 0.94 before treatment to -4.20 ± 0.96 after treatment. During the 6-month treatment period, the height growth rate of 13 children increased significantly (16.6 ± 2.4cm · y-1), which was significantly higher than that of 24 ± 0.6cm · y-1 before treatment (P < 0.001). In addition to a small number of patients with initial injection of the skin and injection site of temporary erythema, no other adverse reactions.